According to the Centers for Disease Control and Prevention (CDC), about 30% of all healthcare-associated enterococcal infections are caused by Vancomycin-Resistant Enterococci (VRE).1
However, VRE can be even more prevalent in high risk groups, such as immunocompromised and ICU patients.The human and financial impact of VRE is high2:
- Attributable mortality: 10%
- Extended length of stay: 6.2 days
- Incremental cost: $12,800
* With EAT (Early Assay Termination), for Positive Results
(1)CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
(2)Carmeli Y, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28;162(19):2223-8.